BeiGene Product Portfolio and Pipeline

Three marketed products in China, three late-stage assets, seven early-stage clinical assets

As of 8/13/19

	ASSETS	PROGRAMS	DOSE ESC. PH1a	DOSE EXPANSION PH1b	DOSE EXPANSION PH2*	PIVOTAL PH2**	PIVOTAL PH3	FILED	COMMERCIAL RIGHTS
Internally Developed	**zanubrutinib** *(BTK)*	**monotherapy**	*R/R MCL, R/R CLL/SLL (NDAs accepted)*						*Global*
			R/R WM						
			WM, 1L CLL/SLL, R/R CLL/SLL						
			R/R MZL						
		+ GAZYVA® *(CD20)*	*R/R FL*						
	tislelizumab *(PD-1)*	**monotherapy**	*R/R cHL, 2L+ UC (NDAs accepted)*						*Global*
			2L NSCLC, 1L HCC, 2L ESCC						
			2L/3L HCC						
			R/R NK/T-cell lymphoma						
		+ chemo	*1L Sq. NSCLC, 1L Non-Sq. NSCLC, 1L NPC, 1L SCLC*						
			1L GC, 1L ESCC						
		+ pamiparib *(PARP)*	*Solid tumors*						
		+ zanubrutinib *(BTK)*	*B-cell malignancies*						
	pamiparib *(PARP)*	**monotherapy**	*1L platinum-sensitive GC maintenance*						*Global*
			2L platinum-sensitive OC maintenance						
			3L gBRCA+ OC						
			Solid tumors						
		+ TMZ *(chemo)*	*Solid tumors*						
		+ RT/TMZ *(RT/chemo)*	*Glioblastoma*						
	lifirafenib *(RAF Dimer)*	**monotherapy**	*B-Raf- or K-RAS/N-RAS-mutated solid tumors*						*Global*
			B-Raf- or K-RAS/N-RAS-mutated solid tumors						
	BGB-A333 *(PD-L1)*	**monotherapy & + tislelizumab**	*Solid tumors*						*Global*
	BGB-A425 *(TIM-3)*	**monotherapy & + tislelizumab**	*Solid tumors*						*Global*
Collaborations	**REVLIMID®**	*(IMiD)*	*R/R MM (marketed), NDMM (marketed), R/R NHL (Ph3)*						*China*
	ABRAXANE®	*(albumin-bound paclitaxel)*	*Breast cancer (marketed), Metastatic pancreatic cancer (filed)*						*China*
	VIDAZA®	*(hypomethylating agent)*	*MDS, AML with 20-30% bone marrow blasts, CMML (marketed)*						*China*
	sitravatinib	*(multi-kinase inhibitor)*[1]	*NSCLC, RCC, OC, Melanoma, HCC/GEJ*						*Asia ex-Japan, NZ, AU*
	ZW25	*(bispecific HER2 antibody)*[2]	*Planned (in Ph2 ex-China by Zymeworks)*						*Asia ex-Japan, NZ, AU*
	ZW49	*(bispecific anti-HER2 ADC)*[2]	*Planned (in Ph1 ex-China by Zymeworks)*						*Asia ex-Japan, NZ, AU*
	avadomide	*(CC-122, CELMoD)*	*Planned (in Ph1b ex-China by Celgene)*						*China*

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. ***REVLIMID® approved as a combination therapy with dexamethasone. 1.Collaboration with Mirati Therapeutics, Inc; APAC study; 2. Collaboration with Zymeworks

BeiGene